Niagen Biosciences, Inc. (NAGE), a global leader in NAD+ science and healthy ageing, announced results from its first randomised controlled trial evaluating Niagen - a patented nicotinamide riboside (NR) supplementation - in individuals with long COVID.
Long COVID continues to impact millions globally, with no established treatments available. Between August and September 2024, the U.S. CDC reported that 5.3% of adults in the country were still experiencing symptoms of long COVID.
Some of the symptoms of long COVID include common fatigue, breathlessness, cognitive impairment or "brain fog" (attention, memory, sleep), muscle aches, depression, and anxiety.
In the study, 58 non-hospitalised adults (average age 45.1 years) with ongoing symptoms after COVID-19 infection were randomly assigned to receive either Niagen NR (2,000 mg/day) for 20 weeks or a placebo for 10 weeks, followed by Niagen NR for another 10 weeks.
According to the study results, while the primary endpoint was not statistically met, participants receiving Niagen NR experienced meaningful within-group improvements in fatigue, sleep quality, and mood.
NAD+ levels increased up to 3.1-fold after 5-10 weeks of Niagen NR supplementation, confirming NAD+ restoration in whole blood, suggesting that restoring the NAD+ system can restore multiple biological pathways implicated in long COVID, noted the company.
Importantly, Niagen NR was well tolerated, with no significant difference in adverse events between treatment arms. The results support further exploration of NAD+ restoration as a therapeutic strategy for long COVID, with larger studies needed to validate these early findings.
Looking ahead, the company plans to expand research into NAD+ biology and its role in post-viral recovery.
The company ended September 30, 2025, with $64.3 million in cash.
NAGE traded in the range of $5.16 - $14.69 over the past year. The stock closed yesterday's trading at $7.18, up 0.28%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.